Premium
Multiple switches between GP 2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study
Author(s) -
Gerdes S.,
Thaçi D.,
Griffiths C.E.M.,
Arenberger P.,
Poetzl J.,
Wuerth G.,
Afonso M.,
Woehling H.
Publication year - 2018
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.14605
Subject(s) - medicine , etanercept , psoriasis area and severity index , biosimilar , adverse effect , immunogenicity , dosing , randomized controlled trial , psoriasis , immunology , antibody , rheumatoid arthritis
Background EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque‐type psoriasis as a part of totality of evidence gathered during the development of GP 2015, an etanercept biosimilar. Objective To demonstrate equivalent efficacy and comparable safety and immunogenicity of GP 2015 and the etanercept originator product ( ETN , Enbrel ® ) and evaluate effects of repeated switching between GP 2015 and ETN . Results for efficacy, safety and immunogenicity during treatment period ( TP ) 2 ( TP 2) are presented pooling the two continued treatment arms (pooled continued) versus the two treatment arms with repeated switches (pooled switched). Methods Patients ( n = 531) were randomized 1:1 to self‐administer GP 2015 or ETN twice‐weekly subcutaneously during TP 1. Patients with a ≥50% improvement in Psoriasis Area and Severity Index ( PASI 50) at week 12 were re‐randomized for TP 2 to continue the same treatment at once‐weekly dosing or to undergo three consecutive treatment switches between GP 2015 and ETN until week 30. Patients continued the last‐assigned treatment during TP 2, until week 52. Results Mean (standard deviation [ SD ]) PASI scores at baseline were similar in patients who underwent multiple switches compared to those with continued treatments during TP 2. During TP 2, PASI 50, PASI 75 and PASI 90 response rates, percent change from baseline in PASI scores and all other efficacy parameters were similar between the pooled switched and pooled continued treatment groups at all time points. The incidence of treatment‐emergent adverse events including injection site reactions was comparable between the pooled switched (36.7%) and pooled continued (34.9%) groups. None of the patients in either treatment group were positive for binding anti‐drug antibodies in TP 2. Conclusion Treatment efficacy, safety and immunogenicity were similar between the pooled continued and pooled switched treatments during TP 2, indicating that there are no effects in the short term on clinical data of multiple switches between GP 2015 and ETN .